Vanzacaftor clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses vanzacaftor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 30 Jun 2025 · Alyftrek · EMEA/H/C/006382 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vanzacaftor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy ParticipantsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT05867147Written as VanzacaftorHow we know
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03912233Written as VX-121How we know
- Study of VX-121 in Healthy Subjects and in Subjects With Cystic FibrosisCompletedPhase 1/2Vertex Pharmaceuticals IncorporatedNCT03768089Written as VX-121 (Suspension)How we know
Codes
What other systems call vanzacaftor · ClinicalTrials.gg INT002186
- MeSH (NLM) C000731979vanzacaftorOne source NLM
- UNII (FDA) COM1POP492VANZACAFTORConfirmed FDA, NLM
- NCI Thesaurus C188560VanzacaftorOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731979 | vanzacaftor | One source NLM |
| UNII (FDA) | COM1POP492 | VANZACAFTOR | Confirmed FDA, NLM |
| NCI Thesaurus | C188560 | Vanzacaftor | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.